Shandong Weigao Group Medical Polymer Company Limited (SHWGY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Shandong Weigao Group Medical Polymer Company Limited (SHWGY) trades at $1.59 with AI Score 41/100 (Grade C). Shandong Weigao Group Medical Polymer Company Limited is a leading Chinese medical device manufacturer. Market cap: $1.79B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for SHWGY: SHWGY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SHWGY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SHWGY: the 1 perspectives are evenly split.
How is this calculated? →Shandong Weigao Group Medical Polymer Company Limited (SHWGY) Healthcare & Pipeline Overview
Shandong Weigao Group Medical Polymer Company Limited, based in China, is a prominent player in the medical device industry, specializing in single-use medical devices, orthopedic products, and interventional products. With a diverse portfolio and a significant presence in hospitals and medical units, the company maintains a strong market position.
What Is the Investment Thesis for SHWGY?
Shandong Weigao Group Medical Polymer Company Limited presents a compelling investment case based on its strong market position in China's growing medical device industry. With a P/E ratio of 9.74 and a profit margin of 15.0%, the company demonstrates financial stability. A dividend yield of 5.06% offers an attractive return for investors. Growth catalysts include expanding its product lines in high-growth areas such as interventional and orthopedic products. Potential risks include regulatory changes in China's healthcare sector and increasing competition from both domestic and international players. The company's beta of 0.19 indicates lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
SHWGY Key Highlights
- Market capitalization of $1.79B, reflecting its significant presence in the medical device market.
- P/E ratio of 9.74, suggesting a potentially undervalued stock compared to its earnings.
- Profit margin of 15.0%, indicating efficient operations and profitability.
- Gross margin of 49.4%, showcasing strong pricing power and cost management.
- Dividend yield of 5.06%, offering a substantial income stream for investors.
Who Are SHWGY's Competitors?
SHWGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANSLF Ansell Limited | $19.58 | +0.00% | $2.77B | 57 |
| ANSLY Ansell Limited | $81.94 | -2.56% | $2.89B | 56 |
| MAHLY MediPal Holdings Corporation | $15.75 | -3.26% | $3.22B | 48 |
| MEPDF MediPal Holdings Corporation | $18.35 | +0.00% | $3.76B | 49 |
| RGEDF Gedeon Richter PLC | $39.76 | +0.30% | $7.27B | 53 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SHWGY's Key Strengths?
- Diversified product portfolio.
- Strong brand recognition in China.
- Extensive distribution network.
- Cost-competitive manufacturing.
What Are SHWGY's Weaknesses?
- High reliance on the Chinese market.
- Limited international presence compared to global competitors.
- Potential vulnerability to regulatory changes in China.
- Exposure to pricing pressures from government healthcare reforms.
What Could Drive SHWGY Stock Higher?
- Expansion of product lines in high-growth segments such as orthopedics and interventional products.
- Penetration into rural markets in China, driven by government initiatives to improve rural healthcare.
- Potential strategic partnerships and acquisitions to expand product portfolio and market reach.
- Focus on export markets, particularly in Southeast Asia and emerging economies.
- Government support for domestic medical device manufacturers.
What Are the Key Risks for SHWGY?
- Increasing competition from domestic and international players in the Chinese market.
- Regulatory changes and pricing pressures in China's healthcare sector.
- Fluctuations in raw material prices, affecting manufacturing costs.
- Product liability claims and recalls.
- Currency risk associated with fluctuations between the U.S. dollar and the Chinese Yuan.
What Are the Growth Opportunities for SHWGY?
- Expansion in Orthopedic Products: The orthopedic device market in China is experiencing significant growth due to an aging population and increasing demand for joint replacement and trauma fixation devices. Shandong Weigao Group Medical Polymer Company Limited can leverage its existing Wego Ortho brand and expand its product offerings to capture a larger share of this market. This includes developing innovative implants and surgical techniques, with a potential market size exceeding $3 billion by 2028.
- Growth in Interventional Products: The interventional medical device market is another high-growth area, driven by increasing adoption of minimally invasive surgical procedures. Shandong Weigao Group Medical Polymer Company Limited can focus on developing and marketing advanced interventional products for cardiovascular, neurovascular, and peripheral vascular diseases. This market is projected to reach $5 billion by 2027, offering substantial growth opportunities.
- Penetration into Rural Markets: China's rural healthcare market represents a significant untapped opportunity. By expanding its distribution network and tailoring its product offerings to meet the specific needs of rural hospitals and clinics, Shandong Weigao Group Medical Polymer Company Limited can drive revenue growth. Government initiatives to improve rural healthcare infrastructure further support this expansion, with a potential market size of $2 billion by 2026.
- Strategic Partnerships and Acquisitions: Shandong Weigao Group Medical Polymer Company Limited can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technological capabilities, and enter new markets. This includes collaborating with international medical device companies and acquiring smaller domestic players with innovative technologies. Successful partnerships could add $500 million to revenue by 2028.
- Focus on Export Markets: Expanding into international markets, particularly in Southeast Asia and emerging economies, presents a significant growth opportunity. By leveraging its cost-competitive manufacturing base and developing products tailored to the needs of these markets, Shandong Weigao Group Medical Polymer Company Limited can diversify its revenue streams and reduce its reliance on the domestic market. Export sales could contribute $300 million to revenue by 2027.
What Opportunities Does SHWGY Have?
- Expansion into high-growth segments such as orthopedics and interventional products.
- Penetration into rural markets in China.
- Strategic partnerships and acquisitions.
- Expansion into international markets.
What Threats Does SHWGY Face?
- Increasing competition from domestic and international players.
- Regulatory changes and pricing pressures in China.
- Fluctuations in raw material prices.
- Potential product liability claims.
What Are SHWGY's Competitive Advantages?
- Diversified product portfolio across multiple medical device segments.
- Established brand recognition and reputation in the Chinese market.
- Extensive distribution network and strong relationships with hospitals and medical institutions.
- Cost-competitive manufacturing base.
What Does SHWGY Do?
Shandong Weigao Group Medical Polymer Company Limited, founded in 2000 and headquartered in Weihai, China, is a comprehensive medical device company focused on the research, development, production, and sale of single-use medical devices. The company operates through several segments, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others. Its extensive product portfolio includes vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, specialized clinical collection kits, wound sutures, wound healing dressings, blood collection, storage, separation, and sterilization equipment. Weigao also provides orthopedic devices, tumor and blood vessel interventional instruments, implantation materials, and hemodialysis equipment. The company serves a wide range of customers, including hospitals, blood stations, and distributors, marketing its products under brands such as Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing. Weigao is also involved in finance leasing, factoring, wholesale of medical devices, and provides asset management and logistics services.
What Products and Services Does SHWGY Offer?
- Develops and manufactures single-use medical devices.
- Produces orthopedic products such as implants and surgical instruments.
- Offers interventional products for cardiovascular and neurovascular procedures.
- Manufactures pharmaceutical packaging products.
- Provides blood management products for collection, storage, and separation.
- Offers a range of other medical products, including anesthesia consumables and ICU equipment.
- Engages in finance leasing and factoring business.
How Does SHWGY Make Money?
- Manufactures and sells a wide range of medical devices and related products.
- Generates revenue through direct sales to hospitals, blood stations, and other medical units.
- Utilizes a distribution network to reach a broader customer base.
- Offers finance leasing and factoring services to support sales and customer relationships.
What Industry Does SHWGY Operate In?
Shandong Weigao Group Medical Polymer Company Limited operates in the rapidly expanding medical device industry in China. The industry is driven by increasing healthcare spending, an aging population, and rising demand for advanced medical technologies. The Chinese government's focus on improving healthcare infrastructure and promoting domestic medical device manufacturers also supports growth. The competitive landscape includes both domestic players and multinational corporations. Weigao's diversified product portfolio and established distribution network position it well to capitalize on these trends.
Who Are SHWGY's Key Customers?
- Hospitals and medical institutions.
- Blood stations.
- Medical device distributors.
- Pharmaceutical companies (for packaging products).
Company Profile
Shandong Weigao Group Medical Polymer Company Limited operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Weihai, CN. The company is led by CEO Rinan Cong. SHWGY has traded publicly since 2012.
How Shandong Weigao Group Medical Polymer Company Limited Is Valued
Shandong Weigao Group Medical Polymer Company Limited carries a market capitalization of $1.79B, placing it in the small-cap category. Relative to its peer group, SHWGY's quantitative score of 41/100 is below the peer average of 53/100.
ROE 7%Key Financial Metrics
Return on equity for Shandong Weigao Group Medical Polymer Company Limited stands at 6.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.5%, showing how much profit it generates from its asset base. SHWGY trades at a trailing price-to-earnings ratio of 7.98, below the Healthcare sector average of ~23x. Its free cash flow yield is 7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 12.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Shandong Weigao Group Medical Polymer Company Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.12 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Shandong Weigao Group Medical Polymer Company Limited revenue of about $14.08B for fiscal 2026, with EPS near $0.00. The estimate reflects 7 contributing analysts.
SHWGY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming growth.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative product pipeline and market expansion.
- Market perception is improving as healthcare demand increases, positioning Shandong Weigao favorably in a growing sector.
- Recent collaborations and partnerships have been well-received, enhancing the company's reputation and potential market reach.
Bear Case
- Concerns about regulatory challenges in the healthcare sector have emerged, creating uncertainty around future operations.
- Social sentiment reflects skepticism regarding the company's ability to scale production effectively amidst rising competition.
- Some community voices express doubts about the sustainability of recent growth, citing potential market saturation as a risk.
- Negative news regarding supply chain disruptions could impact operational efficiency, leading to hesitance among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SHWGY Latest News
No recent news available for SHWGY.
SHWGY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHWGY.
Price Targets
Wall Street price target analysis for SHWGY.
SHWGY MoonshotScore
What does this score mean?
The MoonshotScore rates SHWGY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Rinan Cong
CEO
Rinan Cong serves as the CEO of Shandong Weigao Group Medical Polymer Company Limited. His background includes extensive experience in the medical device industry, with a focus on strategic planning, operational management, and business development. He has been instrumental in driving the company's growth and expansion in the Chinese market. His leadership emphasizes innovation and quality.
Track Record: Under Rinan Cong's leadership, Shandong Weigao Group Medical Polymer Company Limited has achieved significant milestones, including expanding its product portfolio, strengthening its distribution network, and increasing its market share in key segments. He has also overseen the company's international expansion efforts and strategic partnerships. His tenure has been marked by consistent revenue growth and improved profitability.
Shandong Weigao Group Medical Polymer Company Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SHWGY is traded as a Level 1 ADR, meaning it trades over-the-counter (OTC) without the same stringent SEC reporting requirements as listed companies. This allows U.S. investors to invest in Shandong Weigao Group Medical Polymer Company Limited more easily.
- Home Market Ticker: Hong Kong Stock Exchange (SHWG), China
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SHWG
SHWGY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for less transparency and regulatory oversight compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher risk of fraud or manipulation.
- Less regulatory oversight compared to listed companies.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's management team and track record.
- Research the company's industry and competitive landscape.
- Evaluate the company's business model and growth prospects.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Established operating history in the medical device industry.
- Presence in a regulated sector (healthcare).
- Partnerships with reputable organizations.
- Positive media coverage and industry recognition.
- Audited financial statements (if available).
SHWGY Healthcare Stock FAQ
What does Shandong Weigao Group Medical Polymer Company Limited do?
Shandong Weigao Group Medical Polymer Company Limited is a leading Chinese medical device manufacturer specializing in the research, development, production, and sale of single-use medical devices, orthopedic products, and interventional products. The company's extensive product portfolio includes infusion devices, syringes, wound sutures, orthopedic implants, and interventional instruments. Weigao serves hospitals, blood stations, and other medical units, contributing to healthcare delivery across China and expanding into international markets.
What are the main risks for SHWGY?
The main risks for Shandong Weigao Group Medical Polymer Company Limited include increasing competition from both domestic and international players in the Chinese market, regulatory changes and pricing pressures in China's healthcare sector, fluctuations in raw material prices, potential product liability claims, and currency risk associated with fluctuations between the U.S. dollar and the Chinese Yuan. These risks could impact the company's profitability and growth prospects.
What are the key factors to evaluate for SHWGY?
Shandong Weigao Group Medical Polymer Company Limited (SHWGY) holds an AI score of 41/100 (low). Not financial advice.
How frequently does SHWGY data refresh on this page?
SHWGY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SHWGY's recent stock price performance?
Shandong Weigao Group Medical Polymer Company Limited (SHWGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHWGY overvalued or undervalued right now?
Valuing Shandong Weigao Group Medical Polymer Company Limited (SHWGY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SHWGY?
Before investing in Shandong Weigao Group Medical Polymer Company Limited (SHWGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SHWGY to a portfolio?
Key strength of Shandong Weigao Group Medical Polymer Company Limited (SHWGY): Diversified product portfolio. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for SHWGY, which may provide further insights.
- OTC market investments carry higher risks due to limited disclosure and liquidity.